Saudi Journal of Gastroenterology最新文献_第6页

Author response to "Is IBD disk a reliable tool in Saudi Arabia?" 作者回复 "在沙特阿拉伯，IBD 盘是可靠的工具吗？

IF 2.7 4区医学

Saudi Journal of Gastroenterology Pub Date : 2024-01-01 Epub Date: 2024-01-08 DOI: 10.4103/sjg.sjg_414_23

Yaser Meeralam, Adnan B Al-Zanbagi, Mohammed K Shariff

引用次数: 0

Is IBD disk a reliable tool in Saudi Arabia? IBD盘在沙特阿拉伯是一个可靠的工具吗?

IF 2.7 4区医学

Saudi Journal of Gastroenterology Pub Date : 2024-01-01 Epub Date: 2024-01-08 DOI: 10.4103/sjg.sjg_358_23

Zahra A Al Saeed, Turki AlAmeel

引用次数: 0

Saudi consensus guidance for the management of inflammatory bowel disease during pregnancy. 沙特妊娠期炎症性肠病管理共识指南。

IF 1.9 4区医学

Saudi Journal of Gastroenterology Pub Date : 2023-12-15 DOI: 10.4103/sjg.sjg_318_23

Nahla A Azzam, Abdulelah Almutairdi, Hajer Y Almudaiheem, Turki AlAmeel, Shakir A Bakkari, Othman R Alharbi, Khalidah A Alenzi, Maha A AlMolaiki, Bedor A Al-Omari, Rayan G Albarakati, Ahmed H Al-Jedai, Omar I Saadah, Majid A Almadi, Badr Al-Bawardy, Mahmoud H Mosli

{"title":"Saudi consensus guidance for the management of inflammatory bowel disease during pregnancy.","authors":"Nahla A Azzam, Abdulelah Almutairdi, Hajer Y Almudaiheem, Turki AlAmeel, Shakir A Bakkari, Othman R Alharbi, Khalidah A Alenzi, Maha A AlMolaiki, Bedor A Al-Omari, Rayan G Albarakati, Ahmed H Al-Jedai, Omar I Saadah, Majid A Almadi, Badr Al-Bawardy, Mahmoud H Mosli","doi":"10.4103/sjg.sjg_318_23","DOIUrl":"10.4103/sjg.sjg_318_23","url":null,"abstract":"Abstract: The management of inflammatory bowel disease (IBD) in pregnant women is challenging and must be addressed on a patient-by-patient basis. Optimal patient management requires a multidisciplinary team and clear evidence-based recommendations that cater to this subset of patients. In this article, we provide concise guidelines and clinical care pathway for the management of IBD in pregnant women. Our recommendations were developed by a multidisciplinary working group that includes experts from the Saudi Ministry of Health in collaboration with the Saudi Gastroenterology Association and the Saudi Society of Clinical Pharmacology. All recommendations are based on up-to-date information following an extensive literature review. A total of 23 evidence-based expert opinion recommendations for the management of IBD in pregnant women are herein provided.","PeriodicalId":48881,"journal":{"name":"Saudi Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11379253/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138806006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication: A systematic review and meta-analysis of randomized controlled trials. vonoprazan -阿莫西林双重治疗根除幽门螺杆菌:随机对照试验的系统回顾和荟萃分析。

IF 2.7 4区医学

Saudi Journal of Gastroenterology Pub Date : 2023-11-01 DOI: 10.4103/sjg.sjg_153_23

Ben-Gang Zhou, Yu-Zhou Mei, Xin Jiang, Ai-Jing Zheng, Yan-Bing Ding

{"title":"Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication: A systematic review and meta-analysis of randomized controlled trials.","authors":"Ben-Gang Zhou, Yu-Zhou Mei, Xin Jiang, Ai-Jing Zheng, Yan-Bing Ding","doi":"10.4103/sjg.sjg_153_23","DOIUrl":"10.4103/sjg.sjg_153_23","url":null,"abstract":"Background: Vonoprazan-amoxicillin (VA) dual therapy has recently been proposed to eradicate Helicobacter pylori (H. pylori) with controversial results. We, therefore, conducted a meta-analysis to assess the effect of this therapy for H. pylori eradication.Methods: We searched PubMed, Embase, Cochrane Library, and Web of Science database from inception until November 2022, collecting randomized controlled trials (RCTs) comparing VA dual therapy with other regimens for H. pylori eradication. Pooled relative risks (RRs) were calculated using random effects model.Results: Five RCTs were ultimately included. Compared with the vonoprazan-amoxicillin-clarithromycin (VAC) triple therapy, the eradication rate of VA dual therapy was lower in intention-to-treat (ITT) analysis (n = 3 RCTs, RR = 0.94, 95% CI: 0.88-0.99, P = 0.03), but there was no significant difference between them in the per-protocol (PP) analysis (RR = 0.96, 95% CI: 0.91-1.01, P = 0.11). For clarithromycin-resistant H. pylori strains, the eradication rate of VA dual therapy was significantly higher than that of the VAC triple therapy (n = 2 RCTs, RR = 1.20, 95% CI: 1.03-1.39, P = 0.02). Compared with the PPI-based triple therapy (PAC), VA dual therapy had a superior eradication rate (n = 2 RCTs, ITT analysis: RR = 1.13, 95% CI: 1.04-1.23, P = 0.003; PP analysis: pooled RR = 1.14, 95% CI: 1.06-1.22, P = 0.0004). Compared with VAC or PAC triple therapy, VA dual therapy has a similar incidence of total adverse events and compliance.Conclusions: VA dual therapy had a similar effect compared to VAC triple therapy and was superior to PAC triple therapy. Future RCTs are needed to ascertain the optimal dosage and duration of vonoprazan and amoxicillin, and the effect of VA dual therapy compared with the mainstream regimens recommended by current guidelines.","PeriodicalId":48881,"journal":{"name":"Saudi Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10754379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138292083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Practice guidelines for the management of Helicobacter pylori infection: The Saudi H. pylori Working Group recommendations. 幽门螺杆菌感染管理实践指南:沙特幽门螺杆菌工作组的建议。

IF 2.7 4区医学

Saudi Journal of Gastroenterology Pub Date : 2023-11-01 DOI: 10.4103/sjg.sjg_288_22

Fahad Alsohaibani, Musthafa Peedikayil, Abdulaziz Alshahrani, Ali Somily, Raed Alsulaiman, Nahla Azzam, Majid Almadi

{"title":"Practice guidelines for the management of Helicobacter pylori infection: The Saudi H. pylori Working Group recommendations.","authors":"Fahad Alsohaibani, Musthafa Peedikayil, Abdulaziz Alshahrani, Ali Somily, Raed Alsulaiman, Nahla Azzam, Majid Almadi","doi":"10.4103/sjg.sjg_288_22","DOIUrl":"10.4103/sjg.sjg_288_22","url":null,"abstract":"The eradication rates for Helicobacter pylori globally are decreasing with a dramatic increase in the prevalence of antibiotic resistant bacteria all over the world, including Saudi Arabia. There is no current consensus on the management of H. pylori in Saudi Arabia. The Saudi Gastroenterology Association developed these practice guidelines after reviewing the local and regional studies on the management of H. pylori. The aim was to establish recommendations to guide healthcare providers in managing H. pylori in Saudi Arabia. Experts in the areas of H. pylori management and microbiology were invited to write these guidelines. A literature search was performed, and all authors participated in writing and reviewing the guidelines. In addition, international guidelines and consensus reports were reviewed to bridge the gap in knowledge when local and regional data were unavailable. There is limited local data on treatment of H. pylori. The rate of clarithromycin and metronidazole resistance is high; therefore, standard triple therapy for 10-14 days is no longer recommended in the treatment of H. pylori unless antimicrobial susceptibility testing was performed. Based on the available data, bismuth quadruple therapy for 10-14 days is considered the best first-line and second-line therapy. Culture and antimicrobial susceptibility testing should be considered following two treatment failures. These recommendations are intended to provide the most relevant evidence-based guidelines for the management of H. pylori infection in Saudi Arabia. The working group recommends further studies to explore more therapeutic options to eradicate H. pylori.","PeriodicalId":48881,"journal":{"name":"Saudi Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10754383/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33493362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Analysis of the risk of future gastrointestinal surgery in Crohn’s disease with stricture 克罗恩病合并狭窄患者未来胃肠手术的风险分析

4区医学

Saudi Journal of Gastroenterology Pub Date : 2023-10-25 DOI: 10.4103/sjg.sjg_256_23

Wen Zeng, Yong Chen, Bolong Yin, Xue Wen, Jian Xiao, Lian Luo, Haiyuan Tang, He Zheng

{"title":"Analysis of the risk of future gastrointestinal surgery in Crohn’s disease with stricture","authors":"Wen Zeng, Yong Chen, Bolong Yin, Xue Wen, Jian Xiao, Lian Luo, Haiyuan Tang, He Zheng","doi":"10.4103/sjg.sjg_256_23","DOIUrl":"https://doi.org/10.4103/sjg.sjg_256_23","url":null,"abstract":"Abstract Background: Stricture in patients with Crohn’s disease (CD) carries a high risk of CD-related surgery in the course of the disease. The aim of this study was to assess the rate of occurrence of CD-related surgery and to determine baseline risk factors predicting subsequent surgery in this patient group. Methods: Patients registered with stricturing CD were included. All baseline and follow-up data were collected retrospectively. Patients attended the clinic for follow-up at week 14 to assess their response to infliximab (IFX). CD-related surgery was the observational endpoint. Univariate and multivariate Cox regression analyses were used. Results: A total of 123 patients with stricturing CD were included in this study. The cumulative risk of CD-related surgery for years 1–5 after diagnosis was 18.0%, 26.7%, 32.6%, 40.7%, and 46.4%, respectively. Prior gastrointestinal (GI) surgery, low body mass index (BMI), and high platelet count might be risk factors for future CD-related surgery. With 97 participants treated by IFX, prior GI surgery and primary non-response (PNR) to IFX correlated with future CD-related surgery. Conclusion: Prior GI surgery, BMI, and platelet counts were related to future CD-related surgery. Patients who were PNR to IFX had a higher risk of CD-related surgery in the future.","PeriodicalId":48881,"journal":{"name":"Saudi Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135113828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predictors of survival among patients with chronic hepatitis C at a tertiary care center in Oman 阿曼三级保健中心慢性丙型肝炎患者的生存预测因素

4区医学

Saudi Journal of Gastroenterology Pub Date : 2023-09-20 DOI: 10.4103/sjg.sjg_201_23

Halima H. Al-Shuaili, Said A. Al-Busafi, Khalid Al-Naamani, Zakariya Al-Naamani

{"title":"Predictors of survival among patients with chronic hepatitis C at a tertiary care center in Oman","authors":"Halima H. Al-Shuaili, Said A. Al-Busafi, Khalid Al-Naamani, Zakariya Al-Naamani","doi":"10.4103/sjg.sjg_201_23","DOIUrl":"https://doi.org/10.4103/sjg.sjg_201_23","url":null,"abstract":"Abstract Background: Chronic hepatitis C (CHC) is a leading cause of cirrhosis and hepatocellular carcinoma (HCC) worldwide. This study aimed to determine rates and predictors of survival among Omani patients with CHC at a tertiary hospital in Muscat, Oman. Methods: This ambidirectional cohort study included all CHC patients who presented to the Sultan Qaboos University Hospital between January 2009 and December 2017. Baseline demographic, clinical, laboratory, and radiological data were analyzed. Patients were followed-up until death or the endpoint of the study (April 2022) to determine survival and associations with other parameters. Results: A total of 702 CHC patients were included, of which 398 (56.7%) were under 50 years of age and 477 (67.9%) were male. Overall, 180 patients (25.6%) died by the study endpoint. The mean duration of follow-up was 93.3 ± 48.0 months. The 5-year survival rate was estimated to be 80.5%, while the 10-year survival was 73%. Sustained virological response and the absence of diabetes mellitus, chronic kidney disease, HCC, or other malignancies were associated with significantly better overall survival. The 3- and 5-year survival rate of patients with hepatitis C virus (HCV)-related HCC was 46.5% and 27.6%, respectively, with a median survival of 29.5 months. Co-infection with hepatitis B was associated with poor survival among this subgroup; conversely, early HCV screening and the presence of a single HCC lesion were associated with better overall survival. Conclusions: National policies for early CHC screening and rapid treatment are needed to improve survival rates in this population.","PeriodicalId":48881,"journal":{"name":"Saudi Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136265927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial intelligence in endoscopy: Overview, applications, and future directions. 内窥镜检查中的人工智能：概述、应用和未来方向。

IF 2.7 4区医学

Saudi Journal of Gastroenterology Pub Date : 2023-09-06 DOI: 10.4103/sjg.sjg_286_23

Arif A Arif, Shirley X Jiang, Michael F Byrne

引用次数: 0

Artificial intelligence in endoscopy: Overview, applications, and future directions. 人工智能在内窥镜检查中的应用综述及未来发展方向。

IF 1.9 4区医学

Saudi Journal of Gastroenterology Pub Date : 2023-09-01 Epub Date: 2023-09-06 DOI: 10.4103/sjg.sjg_286_23

Arif A Arif, Shirley X Jiang, Michael F Byrne

引用次数: 0

IBD-Disk as a tool estimating the prevalence of inflammatory bowel disease-related disability and associated influencing factors in Saudi Arabia: A cross-sectional study. IBD椎间盘作为评估沙特阿拉伯炎症性肠病相关残疾患病率及相关影响因素的工具：一项横断面研究。

IF 2.7 4区医学

Saudi Journal of Gastroenterology Pub Date : 2023-09-01 Epub Date: 2023-06-08 DOI: 10.4103/sjg.sjg_3_23

Yaser Meeralam, Adnan B Al-Zanbagi, Mona Al Saedi, Walaa Alharthi, Hanadi A Sabbahi, Talal Alhejaili, Mohammed K Shariff

{"title":"IBD-Disk as a tool estimating the prevalence of inflammatory bowel disease-related disability and associated influencing factors in Saudi Arabia: A cross-sectional study.","authors":"Yaser Meeralam, Adnan B Al-Zanbagi, Mona Al Saedi, Walaa Alharthi, Hanadi A Sabbahi, Talal Alhejaili, Mohammed K Shariff","doi":"10.4103/sjg.sjg_3_23","DOIUrl":"10.4103/sjg.sjg_3_23","url":null,"abstract":"Background: Inflammatory bowel disease (IBD) disk is an easy tool to use in clinical practice to measure IBD-related disability, with a score >40 correlating with high daily-life burden. Its use has been limited mainly to the western world. We aimed to estimate the prevalence of IBD-related disability and evaluate the associated risk factors in Saudi Arabia.Methods: In this cross sectional study conducted at a tertiary referral center for IBD, the English IBD disk was translated into Arabic, and patients with IBD were approached to complete it. Total IBD disk score (0 = no disability; 100 = severe disability) was documented and a score of >40 was set as a threshold to estimate the prevalence of disability.Results: Eighty patients with a mean age of 32.5 ± 11.9 years and disease duration of 6 years, including 57% females, were analyzed. The mean IBD-disk total score was 20.70 ± 18.69. The mean subscores for each function within the disk ranged from 0.38 ± 1.69 for sexual functions to 3.61 ± 3.29 for energy. The overall prevalence of IBD-related disability was 19% (15/80 scoring >40) and was much higher in active disease, in males and in IBD of long duration (39%, 24%, and 26%, respectively). A clinically active disease, high CRP, and high calprotectin were strongly associated with higher disk scores.Conclusion: Although the overall mean IBD disk score was low, nearly 19% of our population had high scores signifying a high prevalence of disability. As demonstrated by other studies, active disease and high biomarkers were significantly associated with higher IBD-disk scores.","PeriodicalId":48881,"journal":{"name":"Saudi Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41136456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1